Authors: Aya Nozaki Takao Ando Satoru Akazawa Tsuyoshi Satoh Ikuko Sagara Ichiro Horie Misa Imaizumi Toshiro Usa Robert T Yanagisawa Atsushi Kawakami
Publish Date: 2015/05/30
Volume: 51, Issue: 1, Pages: 140-147
Abstract
Central diabetes insipidus CDI is characterized by polyuria and polydipsia due to a deficiency of vasopressin Currently the treatment goal for CDI is improvement of quality of life QOL by desmopressin DDAVP without developing hyponatremia However there is no reliable measure for QOL in CDI patients We evaluate our original questionnaire for QOL consisting of 12 questions focusing on polyuria polydipsia and DDAVP treatment in CDI patients who underwent a switch from nasal spray to oral disintegrating tablets of DDAVP Twentyfive CDI patients under nasal DDAVP treatment six with newly developed CDI and 18 healthy individuals without known polyuric/polydipsic disorders as control subjects were enrolled QOL scores were determined by our questionnaire at the enrollment and 3 months after the start of oral DDAVP treatment and were examined by the Wilcoxon signedrank test Eleven questions detected improvement in QOL The sum of the QOL scores of the eleven questions increased from 292 ± 56 under nasal to 368 ± 45 under oral DDAVP p 0001 There were no clinically relevant changes in serum levels of Na After eliminating two questions about DDAVP treatment the sum of QOL scores was 153 ± 65 in untreated CDI patients 244 ± 52 in those with nasal treatment 289 ± 49 in those with oral DDAVP and 295 ± 36 in healthy controls The difference among groups was significant p 005 in Steel–Dwass test except between patients treated with oral DDAVP and healthy controls Our questionnaire can be used to accurately assess QOL in CDI patients
Keywords: